Description
In this era of finite budgets, healthcare rationing, medication shortages, and the global aging and burgeoning of populations, numerous stakeholders in the healthcare arena must understand the basic principles of pharmacoeconomics and how these may be correctly applied to facilitate drug development, rationing, patient segmentation, disease management, and pricing model development.
Pharmacoeconomics: From Theory to Practice, Second Edition focuses on how to more efficiently and rationally leverage these healthcare resources, not by restricting access to necessary services, but by using them more efficiently. This updated volume arms decision makers with the tools they need to make wise choices in an area where the stakes are extremely high—the health of the global population.
Key Features:
- Introduces the major concepts and principles of Pharmacoeconomics
- Gives updated information about pharmacoeconomic models, value-based pricing, novel modelling methodologies and international utilization of these modalities in government, the pharmaceutical industry, and health care settings
- Demonstrates the full range of ethical and moral issues, as well as overall public health and commercial concerns that are often involved in decisions entailing pharmacoeconomic issues
- Presents both theory and methodology discussions, including real-world examples, in each chapter
'The methods and application of pharmacoeconomics are rapidly evolving, so the new edition of this textbook is very timely. It provides an excellent introduction for those new to the field, whether they be students, professionals within the pharmaceutical industry, or health care professionals more generally. A particularly useful feature of the book is that it gives an introduction both to the main methods used in pharmacoeconomics studies and how these studies are used in decisions about the reimbursement or appropriate use of medicines in several countries.'
- Michael Drummond, Professor of Health Economics, University of York
Table of Contents
Introduction to Pharmacoeconomics; Decision Modeling Techniques; Multiple Criteria Decision Analysis (MCDA); Cost of Illness; Markov Modeling in Decision Analysis; Novel Modeling Methods (DICE); Retrospective Database Analysis; What is Cost-Minimization Analysis?; Cost-Effectiveness Analysis; Budget Impact Analysis; Cost-Utility Analysis: A Case Study of a Quadrivalent Human Papillomavirus Vaccine; Some Problems/Assumptions in Pharmacoeconomic Analysis; Patient-Reported Outcome Measures; Sensitivity Analysis; Use of Pharmacoeconomics in Drug Reimbursement in Australia, Canada, and the United Kingdom: What Can We Learn from International Experience?; Implementation of Value Frameworks in Reimbursement Decisions in the US and Beyond, NICE (UK) and PBAC (Australia; Pharmacoeconomics in Disease Management: Practical Applications and Persistent Challenges; Computer Aided Decision Making from Drug Discovery to Pharmacoeconomics; Speculations on the Future Challenges and Value of Pharmacoeconomics.
